Is Eris Lifesciences the Best Stock in Its Sector? A Look at the Numbers

Is Eris Lifesciences the best stock in its sector? The stock trades on the NSE at Rs 1,180 as of 12 October 2026, within its 52-week range of Rs 1,141.00 to Rs 1,740.00. Eris Lifesciences Ltd is an Indian pharmaceutical company focused on branded formulations in chronic and sub-chronic therapies such as cardiac, anti-diabetic, vitamins and gastrointestinal products.

Eris Lifesciences sits in the Healthcare sector, and its 15.87% ROE and 24.44x P/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector's Industry P/E benchmark.

Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers

Click Here – Get Free Investment Predictions

About Eris Lifesciences

Eris Lifesciences Ltd is an Indian pharmaceutical company focused on branded formulations in chronic and sub-chronic therapies such as cardiac, anti-diabetic, vitamins and gastrointestinal products. The company has expanded both organically and through acquisitions of brands and businesses, and a branded chronic portfolio tends to bring repeat prescription demand. The stock trades about 32 percent below its 52-week high and about 3 percent above its 52-week low. At a market capitalisation of Rs 16,269 Cr, it is tracked as part of the Healthcare sector on Univest.

Is Eris Lifesciences the Best Stock in Its Sector?

Eris Lifesciences makes its case as the best stock in its sector primarily on valuation relative to its Industry P/E, combining a 15.87% ROE with a 24.44x P/E against the sector's 36.69x Industry P/E. Eris Lifesciences' 24.44x P/E is below the 36.69x Industry P/E, supported by a 15.87% ROE, though a 0.60 debt to equity ratio reflects acquisition-led growth.

Metric	Eris Lifesciences
CMP (NSE)	Rs 1,180.40
52-Week High / Low	Rs 1,740.00 / Rs 1,141.00
Market Cap	Rs 16,269 Cr
P/E (TTM) vs Industry P/E	24.44x vs 36.69x
P/B	4.17
ROE	15.87%
EPS (TTM)	Rs 47.98
Dividend Yield	0.61%
Debt to Equity	0.60

Compare Eris Lifesciences Against Other Healthcare Sector Stocks

How Eris Lifesciences Compares Against Its Healthcare Sector Peers

The table below sets Eris Lifesciences against 2 other Healthcare sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.

Company	Market Cap (Rs Cr)	P/E	ROE	Debt to Equity
Eris Lifesciences	16,269	24.44	15.87%	0.60
Alkem Laboratories	62,954	28.56	16.66%	0.15
Ajanta Pharma	42,624	37.56	23.33%	0.06
Peer average (2 companies)	-	33.06	19.99%	0.10

Against this peer set, Eris Lifesciences's 15.87% ROE is below the 19.99% peer average, and its P/E of 24.44x runs below the peer average of 33.06x. Eris Lifesciences' 24.44x P/E is below the 36.69x Industry P/E, supported by a 15.87% ROE, though a 0.60 debt to equity ratio reflects acquisition-led growth.

What Makes Eris Lifesciences Worth Watching in Healthcare

• Sector discount: A 24.44x P/E against a 36.69x Industry P/E sits meaningfully below the benchmark.
• Return ratio: A 15.87% ROE points to solid profitability.
• Chronic focus: Chronic therapies such as cardiac and anti-diabetic tend to see repeat prescriptions.

Eris Lifesciences Valuation: Is It Justified?

Eris Lifesciences' 24.44x P/E is below the 36.69x Industry P/E, supported by a 15.87% ROE, though a 0.60 debt to equity ratio reflects acquisition-led growth. As with any single stock, investors should weigh this against their own valuation discipline and risk appetite rather than the sector label alone.

Also read – Is VIP Clothing the Best Stock in Its Sector? A Look at the Numbers

Download the Univest iOS App or Univest Android App to track Eris Lifesciences and other Healthcare sector stocks.

How to Track Eris Lifesciences Before You Invest

Before deciding whether Eris Lifesciences deserves its label as the best stock in its sector for your own portfolio, compare it directly against Healthcare sector peers using the steps below.

1. Open the Univest Screener and search for Eris Lifesciences to view live price, valuation ratios, and peer comparisons within the Healthcare sector.
2. Compare its P/E, P/B, and ROE against other Healthcare sector stocks before deciding if the current valuation fits your strategy.
3. Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
4. Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.

Conclusion

Eris Lifesciences earns a place in the best stock in its sector conversation on the strength of a 15.87% ROE and a P/E of 24.44x against a 36.69x Industry P/E, with named peer comparisons in this article backing up that picture. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.

Is Eris Lifesciences the best stock in its sector?

Ans. Eris Lifesciences has a 15.87% ROE and trades at 24.44x P/E against a 36.69x Industry P/E, and compares below the peer average ROE of 19.99% in this article's named comparison, so the answer depends on what an investor is prioritising.

What is the current share price of Eris Lifesciences?

Ans. Eris Lifesciences was trading at Rs 1,180.40 on the NSE as of 12 October 2026, within its 52-week range of Rs 1,141.00 to Rs 1,740.00.

What sector does Eris Lifesciences belong to?

Ans. Eris Lifesciences is classified under the Healthcare sector on Univest.

How does Eris Lifesciences compare to its sector peers on P/E?

Ans. Eris Lifesciences's P/E of 24.44x is below the 33.06x average of the 2 named peers compared in this article.

What is Eris Lifesciences's return on equity?

Ans. Eris Lifesciences reported a return on equity of 15.87%, which is below the 19.99% average of its named peers in this comparison.

Should I invest in Eris Lifesciences based on its sector position?

Ans. Eris Lifesciences's sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.

{"@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [{"@type": "Question", "name": "Is Eris Lifesciences the best stock in its sector?", "acceptedAnswer": {"@type": "Answer", "text": "Eris Lifesciences has a 15.87% ROE and trades at 24.44x P/E against a 36.69x Industry P/E, and compares below the peer average ROE of 19.99% in this article's named comparison, so the answer depends on what an investor is prioritising."}}, {"@type": "Question", "name": "What is the current share price of Eris Lifesciences?", "acceptedAnswer": {"@type": "Answer", "text": "Eris Lifesciences was trading at Rs 1,180.40 on the NSE as of 12 October 2026, within its 52-week range of Rs 1,141.00 to Rs 1,740.00."}}, {"@type": "Question", "name": "What sector does Eris Lifesciences belong to?", "acceptedAnswer": {"@type": "Answer", "text": "Eris Lifesciences is classified under the Healthcare sector on Univest."}}, {"@type": "Question", "name": "How does Eris Lifesciences compare to its sector peers on P/E?", "acceptedAnswer": {"@type": "Answer", "text": "Eris Lifesciences's P/E of 24.44x is below the 33.06x average of the 2 named peers compared in this article."}}, {"@type": "Question", "name": "What is Eris Lifesciences's return on equity?", "acceptedAnswer": {"@type": "Answer", "text": "Eris Lifesciences reported a return on equity of 15.87%, which is below the 19.99% average of its named peers in this comparison."}}, {"@type": "Question", "name": "Should I invest in Eris Lifesciences based on its sector position?", "acceptedAnswer": {"@type": "Answer", "text": "Eris Lifesciences's sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor."}}]}